The Landscape Of AI And Real-World Evidence
The race to find medical treatments for Covid-19—and future pandemics—is on, driving renewed investments by the healthcare and pharmaceutical industries in Real-World Data (RWD) and Real-World Evidence (RWE). A new report on AI and the real-world studies industry, from Deep Pharma Intelligence (DPI), provides fresh insights into this rapidly evolving patient-centric approach to increasing R&D efficiency, accelerating the introduction of new drugs, and improving health outcomes.
Report Maps Out RWS Sector, Forecasts 40% Annual Growth in China
The seminal report titled ‘Landscape of AI Technology Companies in Real-World Studies Industry,’ was jointly produced by leading Biotech and Health tech investment intelligence agency Deep Pharma Intelligence (DPI), Shanghai-based medical firmEvomics Medical, which applies artificial intelligence (AI) diagnosis and clinical services, and the Yuan, an open forum on a quest to make AI also stand for ‘All-Inclusive.’
The Rise of AI in Pharma
While the global pandemic appeared to be a hard blow for the majority of economic sectors, the biotech market was on the rise – not only reaching record breaking values for the biotech stock index, but also showing extraordinary deal-making activity on the frontiers of venture capital investments and initial public offerings (IPOs).
The rising trend was also observed for the sector of pharmaceutical artificial intelligence (AI).
Deep Pharma Intelligence AI in Pharma Webinar Summary
Day 1 (Top AI in Pharma Deals, Trends & Partnerships 2020-Q1 2021) featured presentations and a roundtable discussion on the biggest deals, partnerships, collaborations, and industry events in the AI in Pharma sector from 2020 - 2021.
Day 2 (Investment and M&A Deals: AI in Pharma Market 2021) featured talks and a panel discussion on key players, trends in the private equity and venture capital ecosystem, focusing on the increasing market maturation of AI in Pharma, and key take-aways for investors in 2021.
Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022
The report provides an overview and brief assessment of 5 highly impactful and promising medical hardware technologies to be watched in 2021-2022, and the companies behind their development and commercialization. [..] We consider these 5 companies to be well-balanced, strong, and well-positioned enough to successfully implement product development and commercialization strategies, and achieve prominent growth dynamics.
Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022
The report features companies’ business background, brief history, state of research and development and intellectual property (IP), overview of companies’ product and value offerings outlining technological novelty, summary of their major partnerships and customers, the history of funding rounds and IPO-related information, dynamics of R&D spending over years, property analysis, and brief SWOT analysis.
Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022
All the reviewed companies [..] possess strong R&D basis, have well-developed level of know-how and intellectual property, favorable growth drivers, and large total addressable markets for their products and services. The selected companies have strong innovative components and long histories of scientific or technological research, which give them tangible competitive edge in gaining market share and positioning their brands on the global scale.
Recordings from the last webinar "AI in Pharma, Biotech and Drug Discovery Industry 2020" are available now
Deep Pharma Intelligence team introduced the company and its founding partners Deep Knowledge Analytics and BiopharmaTrend, and shared their insights and statistics about the Pharmaceutical Artificial Intelligence (AI) sector, including current trends, leaders in the “AI Race”, key R&D partnership and major investment deals, and latest industry developments. The company has paid particular attention to investment opportunities in this increasingly attractive market.
Deep Pharma Intelligence in the Drug Discovery World's article
"Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical Report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and Big Data analytical Dashboard."
Deep Knowledge Analytics Pharma Division and BiopharmaTrend Form New Joint Venture: Deep Pharma Intelligence
Deep Knowledge Analytics and BPT Analytics (BioPharmaTrend), two UK-based leaders in Pharma and Healthcare Analytics and market research have joined forces to incorporate a new entity, Deep Pharma Intelligence Ltd, which has been spun out of Deep Knowledge Analytics Pharma Division and incorporated in London, UK in order to provide actionable toolsets to optimize strategic decision making in the AI in Pharma and Healthcare sectors.
Release of New Report "AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview Q4 2021"
AI System Has Designed, Synthesized and Surpassed Independent Validation of a New Drug in Just 21 Days
September 3, 2019, London, UK: Deep Knowledge Analytics acknowledges the new ground-breaking achievement of Insilico Medicine, which succeeded to design, synthesize and validate a novel drug candidate end-to-end in just 46 days, which is 15 times faster compared to what it typically takes even for the top pharma corporations capable to conduct the most efficient R&D process.
Pharma’s AlphaGo Moment: For the First Time, Artificial Intelligence Has Designed a New Drug in 21 Days
While it typically takes 2-3 years to go from initial drug discovery to preclinical validation, one AI for Drug Discovery company has done the same in less than 2 months end-to-end, which is 15 times faster compared what it typically takes even for the best pharma corporations capable to conduct the most efficient R&D process.
A breakthrough in imaginative artificial intelligence with experimental validation to accelerate drug discovery
September 3rd, 2019, London, UK: Deep Knowledge Analytics salutes its parent company, Deep Knowledge Ventures, in the landmark Nature Biotechnology publication of its portfolio company, Insilico Medicine, demonstrating the design, synthesis and preclinical validation of a novel drug candidate in just 46 days.
Pharmaceutical Technology quoted AI-Friendly CEOs and Board Members report
Deep Knowledge Analytics also released a report examining AI, which examined practices at 50 pharmaceutical companies to identify leaders who are most actively driving the use of AI in their organizations.
Importance of senior management
The goal of this research is to benchmark the impact of management support on the use of AI and overall efforts to increase R & D efficiency, according to Margaretta Colangelo, managing partner at Deep Knowledge Ventures.
Deep Knowledge Ventures Founding Partner Presents on State of UK AI Industry in the UK Parliament
On October 26, 2018, Dmitry Kaminskiy, Founding Partner of Deep Knowledge Ventures, presented keypoints from the landmark 2200 page AI Industry in UK Q3 2018 report jointly produced by Big Innovation Centre and Deep Knowledge Analytics in coordination with the All-Party Parliamentary Group (APPG) on AI, alongside Lord Clement-Jones, CBE (Co-Chairman of the APPG on AI) and Birgitte Andersen (CEO of BIC), at a meeting convened to announce the report’s publication.
Artificial Intelligence and Machine Learning for Advanced Drug Discovery
On 28-29 May in London, global pharma leaders gather at the 2nd Annual meeting dedicated to Artificial Intelligence and Machine Learning for Advanced Drug Discovery and Development to exchange experience and share knowledge through panel discussions, practical case studies, interactive sessions. Delegates will have the opportunity to pose their biggest questions directly to industry experts in small working groups on the topic of their choice during Choose & Join interactive roundtable discussions.
MIT School of Engineering first
quarter 2019 awards
Members of the MIT engineering faculty receive many awards in recognition of their scholarship, service, and overall excellence. Every quarter, the School of Engineering publicly recognizes their achievements by highlighting the honors, prizes, and medals won by faculty working in our academic departments, labs, and centers.
Regina Barzilay, Manolis Kellis, Tommi Jaakola and Peter Szolovits were named among “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare” by Deep Knowledge Analytics on Feb. 1.
AI for Drug Discovery 2019:
Intelligence, Analysis, Forecasts
.png)
The AI for Drug Discovery space is evolving rapidly. Taking into account the progress in the last three years, it's reasonable to expect that really significant results could be achieved in the next three years. In the first quarter of this year, the number of new research centers increased by 10, the number of companies in the space increased by 20, and the number investment funds investing in the space increased by 30.
AI for drug discovery will be driven by biopharma and the rise of
Asian tigers, says Insilico CEO
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024...
Specialized Metrics To Properly
Assess AI-Pharma Startups
The level of sophistication used in due diligence should be on a par with the level of complexity in a given industry. AI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous.
Discovering new drugs using AI is one of the most challenging areas in biological sciences...
The 100 Leading Pioneers Of AI Drug Development
Deep Knowledge Analytics picked the 'Top 100 AI Leaders in Drug Discovery and Advanced Healthcare’ out of an initial pool of 500 outstanding candidates. Unless a new AI winter wind blows and sweeps over the science explorers, their work is quite likely to enhance the quality of life surpassing the most vivid science fiction imagination...
World's Top 20 AI Drug Development Companies
Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials. Moreover, 75% of newly approved drugs are unable to cover the cost of development and some analysts predict that ROI in pharmaceutical R&D may hit zero by 2020...
MIT acknowledged AI ranking
made by Deep Knowledge Analytics
This week four CSAIL faculty were named among the top 100 global leaders in artificial intelligence for health, according to a new report developed by a top technology think-tank.
Deep Knowledge Analytics’s “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare” (PDF) looked at scientists, clinicians and technologists across academia, pharma, and AI companies...
An Insight Of AI's Penetration In Drug Development Market
A recent article about AI-based drug development, indicates the progressive use of A.I. technologies for the drug production industry, mining the huge amount of data collected from the pharmaceutical companies’ data centers. Thanks to Deep Knowledge Ventures which a couple of days ago updated their research data, we took the opportunity to delve into the latest developments of this market...
Pharma companies put faith in AI for breakthroughs
.jpg)
Billions are being bet to find the next revolutionary drug. In 2013, US start-up Berg was asked by the Department of Defense to help improve the detection of prostate cancer, a disease common among pilots. Less than five years later, an artificial intelligence-driven tool has been tested on more than 1,000 patients with promising results...
Elsevier quoted DKA Pharma Division article on the Pharma R&D Today blog
“China’s ability to generate massive amounts of real-time medical data from more than 1 billion people in the local population, stimulated by rather flexible privacy laws is driving advancement,” writes Margaretta Colangelo of Deep Knowledge Ventures. Though she says that government programs are also helping to grow local AI and data science talent, Colangelo also warns that China is currently lagging behind its competitors in pharma and biotech innovation, which could limit its progress.
BPT Analytics Introduces Cloud-Based Business Intelligence Dashboard
BPT Analytics Ltd. (BiopharmaTrend) is a provider of web-based business intelligence dashboards for the pharmaceutical sector. Recently the company has launched a cloud-based analytics dashboard known as a Landscape of Artificial Intelligence (AI) in Pharma R&D.
Breaking Through The Glass Ceiling - A Spring For Women In Artificial Intelligence
After the COVID-19 pandemic is over and the economy reopens, many students will resume work on their careers. But for many young people, their priorities are going to shift. After seeing the pain and suffering caused by a single invisible enemy, some will naturally prioritize biomedical research over other easier and more lucrative trades, like law and finance.
Digital Science announces winners of its prestigious Catalyst Grant award
Research industry technology company Digital Science has revealed the latest winners of its prestigious Catalyst Grant award: BPT Analytics, Intoolab and MLprior have been awarded a grant. An international initiative to develop innovative projects and technologies The Catalyst Grant offers an award of up to £25,000 or $30,000 for concepts with the potential to transform scientific research.
From artificial intelligence and AI scientists to pharmaceutical analytics – 2019 Catalyst Grant Winners
BPT Analytics, Intoolab and MLprior, three projects aiming to disrupt the academic space, are the latest recipients of the Catalyst Grant award for innovative startups. Research industry technology company Digital Science has today revealed the latest winners of its prestigious Catalyst Grant award: BPT Analytics, Intoolab and MLprior have been awarded a grant.